Vectus Biosystems Limited
Vectus Biosystems Limited (VBS.AX) Financial Performance & Income Statement Overview
Analyze Vectus Biosystems Limited (VBS.AX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Vectus Biosystems Limited (VBS.AX) Income Statement & Financial Overview
Explore comprehensive income reports for Vectus Biosystems Limited VBS.AX, broken down by year and quarter.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $393707.00 | $490499.00 | $648175.00 | $775265.00 |
| Cost of Revenue | $0.00 | $0.00 | $28748.00 | $24970.00 |
| Gross Profit | $393707.00 | $490499.00 | $619427.00 | $750295.00 |
| Gross Profit Ratio | $1.00 | $1.00 | $0.96 | $0.97 |
| R&D Expenses | $478693.00 | $536846.00 | $614200.00 | $716504.00 |
| SG&A Expenses | $927922.00 | $1.08M | $1.18M | $1.34M |
| Operating Expenses | $1.41M | $1.61M | $1.79M | $2.06M |
| Total Costs & Expenses | $1.41M | $1.61M | $1.82M | $2.08M |
| Interest Income | $0.00 | $39193.00 | $37665.00 | $48717.00 |
| Interest Expense | $0.00 | $5239.00 | $3465.00 | $5209.00 |
| Depreciation & Amortization | $11919.00 | $30087.00 | $28748.00 | $24970.00 |
| EBITDA | -$1.01M | -$1.12M | -$1.15M | -$1.27M |
| EBITDA Ratio | -$2.57 | -$2.29 | -$1.77 | -$2.65 |
| Operating Income | -$1.01M | -$1.12M | -$1.82M | -$2.08M |
| Operating Income Ratio | -$2.57 | -$2.29 | -$2.81 | -$2.68 |
| Other Income/Expenses (Net) | -$470228.00 | -$486632.00 | $35077.00 | $45213.00 |
| Income Before Tax | -$1.48M | -$1.61M | -$1.79M | -$2.04M |
| Income Before Tax Ratio | -$3.77 | -$3.28 | -$2.76 | -$2.63 |
| Income Tax Expense | -$383177.00 | -$451306.00 | -$609633.00 | -$724843.00 |
| Net Income | -$1.10M | -$1.16M | -$1.18M | -$1.31M |
| Net Income Ratio | -$2.79 | -$2.36 | -$1.82 | -$1.69 |
| EPS | -$0.02 | -$0.02 | -$0.02 | -$0.02 |
| Diluted EPS | -$0.02 | -$0.02 | -$0.02 | -$0.02 |
| Weighted Avg Shares Outstanding | $53.14M | $53.21M | $53.19M | $53.19M |
| Weighted Avg Shares Outstanding (Diluted) | $53.23M | $53.21M | $53.19M | $53.19M |
Over the last four quarters, Vectus Biosystems Limited's revenue moved from $775265.00 in Q4 2023 to $393707.00 in Q2 2025. Operating income in Q2 2025 was -$1.01M, with a strong operating margin of -257%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Vectus Biosystems Limited remained robust at -$1.01M, reflecting operational efficiency. Net income rose to -$1.10M, with an EPS of -$0.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan